ScreenerHero

CPHIChina Pharma Holdings, Inc.

AMEX · US · Healthcare · Drug Manufacturers - Specialty & Generic · chinapharmaholdings.com
0.9800USD-9.26%Mkt Cap: 42.16M $P/E: —

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injecta…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap42.16M $
Enterprise Value49.05M $
Revenue (TTM)3.91M $
Gross Profit-131.95K $
Net Income (TTM)-3.19M $
Revenue/Share0.1990 USD
Last Price0.9800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees215
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG0.16
EV/EBITDA-34.05
EV/Revenue12.53
P/S10.77
P/B1.10
EPS (TTM)-0.42
EPS (Forward)—
52W Range
0.38003% of range19.19
52W High19.19 USD
52W Low0.3800 USD
Profitability
Gross Margin-3.18%
Oper. Margin-150.98%
EBITDA Margin-36.81%
Profit Margin-76.91%
ROE-14.02%
ROA-10.28%
Growth
Revenue Growth-7.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF148.26K $
CapEx (TTM)137.25K $
FCF Margin36.27%
FCF Yield3.37%
Net Debt3.45M $
Net Debt/EBITDA-2.39
Balance Sheet
Debt/Equity0.17
Current Ratio0.26
Quick Ratio0.07
Book Value/Sh0.8930 USD
Cash/Share0.0070 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.43.02M
Float3.30M
Insiders89.63%
Institutions0.47%
Short Interest
Short Ratio0.0d
Short % Float0.42%
Short % Out.0.29%
Shares Short115.66K
Short (prev mo.)24.50K
Technical
SMA 501.107 (-11.5%)
SMA 2001.013 (-3.2%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)9.24M
Avg Vol (10d)1.61M
Technical Indicators
RSI (14)47.0
MACD-0.0569
MACD Signal-0.0091
MACD Hist.-0.0478
BB Upper1.586 USD
BB Middle1.210 USD
BB Lower0.8332 USD
BB Width62.23%
ATR (14)0.5335 USD
Vol Ratio (20d)0.10x